Q-omics provides the consensus-scored BBS4 profile across patient tissues and cancer cell-line models. BBS4 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in UCEC. Among the 18 cancer types available for tumor–normal comparison, BBS4 is differentially expressed in 11, with the highest sampling consensus in KICH. Additionally, BBS4 RNA expression shows 20,870 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight UCEC, KICH, and UVM as cancer lineages where BBS4 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for BBS4 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes BBS4 survival associations across molecular data types. BBS4 RNA expression shows survival associations in the most cancer types (21), followed by mutation status (6) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible BBS4 RNA expression–survival associations across cancer types. High BBS4 expression shows unfavorable associations in LGG, UVM and SCLC, but favorable associations in UCEC, ESCA and PAAD. The UCEC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify UCEC as the clearest survival context for BBS4 RNA expression.
This table summarizes BBS4 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 5. The strongest signals are observed in THCA for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for BBS4. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. BBS4 shows lower tumor expression in KICH, THCA and LUSC and higher tumor expression in HNSC, LIHC and CHOL. The KICH box plot shows higher BBS4 RNA expression in normal versus tumor tissue (log2 FC = −1.634, t-test p < 0.001).
This table shows molecular features associated with BBS4 in patient tissues and cancer cell lines. In patient samples, BBS4 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, BBS4 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in CNS, while CRISPR and shRNA rows add functional-dependency signals in UPPER_AERODIGESTIVE_TRACT and LARGE_INTESTINE.
